Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)

Inclusion Criteria:

* Histologically or cytologically proven squamous cell carcinoma of the head \& neck.
* Age greater than or equal to 18.
* ECOG performance status of 0 to 1
* Measurable malignant disease.
* Patients that have failed at least one platinum-containing regimen and have received no more than three prior regimens and do not have other curative treatment options.
* Patients must be at least 2 wks post surgery or radiation therapy
* Patients must be at least 4 weeks post chemotherapy
* Meets protocol requirements for specified laboratory values.
* Written informed consent and cooperation of patient.
* Appropriate use of effective contraception if of childbearing potential.
* No investigational drugs of any type within 30 days prior to administration.

Exclusion Criteria:

* Prior exposure to farnesyl transferase inhibitors
* Medical conditions that would interfere with taking oral medications.
* Patients with significant QTc prolongation at baseline (\>500 msec.)
* Pregnant or nursing women
* Known HIV positivity or AIDS-related illness.
* Concomitant chemotherapy, hormonal therapy, radiotherapy or immunotherapy
* Patients with any signs of involvement of the dura, meninges, or brain.
* Patients with squamous cell carcinoma of the nasopharynx
* Patients who currently have other cancers or have been treated in the last 5 years for any other malignancy.